Evidence map›Paper›PMID 29173024›Full record

ArticleCancer biology & therapy2017

Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9.

Huidi Liu, Zheng Zeng, Siwen Wang, Ting Li, Emilio Mastriani, Qing-Hai Li, Hong-Xia Bao, Yu-Jie Zhou, Xiaoyu Wang, Yongfang Liu and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Ethanolic Extract of Pomegranate (Animals : an open access journal from MDPI · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Application Value of Antimicrobial Peptides in Gastrointestinal Tumors.International journal of molecular sciences · 2023
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Huidi Liua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Zheng Zenga Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Siwen Wanga Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Ting Lia Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Emilio Mastriania Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Qing-Hai Lia Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Hong-Xia Baoa Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Yu-Jie Zhoua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Xiaoyu Wanga Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Yongfang Liua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Wei Liua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Sijing Hua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Shan Gaoa Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Miao Yua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Yingying Qia Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Zhihang Shena Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Hongyue Wanga Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Tingting Gaoa Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Lingqin Donga Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Randal N Johnstond Department of Biochemistry and Molecular Biology , University of Calgary , Calgary , Alberta , Canada.
Shu-Lin Liua Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) , Harbin Medical University , Harbin , Heilongjiang Province , China.
Harbin Medical University · CNUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the third most common cancer in the female reproductive organs and epithelial ovarian cancer has the highest lethality of all gynecological cancers. Pomegranate fruit juice (PFJ) has been shown to inhibit the growth of several types of cancer other than ovarian cancer. In this study, we exposed the ovarian cancer cell line A2780 to PFJ and two of its components (ellagic acid and luteolin). MTT and wound healing assays demonstrated that all three treatments suppressed the proliferation and migration of the ovarian cancer cells. In addition, western blotting and ELISA assays showed that the expression levels of MMP2 and MMP9 gradually decreased after treatment with increasing concentrations of ellagic acid and luteolin. To confirm our findings in the in vitro experiments, we used another ovarian cancer cell line, ES-2, in nude mice experiments. All three treatments inhibited tumor growth without obvious side-effects. Furthermore, compared with the control group, the expression levels of MMP2 and MMP9 were depressed. Ellagic acid induced a greater effect than luteolin, suggesting that ellagic acid might be a promising candidate for further preclinical testing for treatment of human ovarian cancer.

Indexed as

AnimalsCell Line, TumorCell MovementCell ProliferationEllagic AcidFemaleGene Expression Regulation, NeoplasticHumansLuteolinLythraceaeMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceNeoplasm MetastasisOvarian NeoplasmsXenograft Model Antitumor AssaysEllagic AcidLuteolinMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanMMP9 protein, humanellagic acidluteolinMMP2MMP9ovarian cancerpomegranate fruit juice

Identifiers

PMID29173024
PMCPMC5718784
OpenAlexW2768342523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.